Artículos de revistas sobre el tema "Marine sarcoma"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Marine sarcoma".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Su, Bor-Chyuan, Giun-Yi Hung, Yun-Chieh Tu, Wei-Chen Yeh, Meng-Chieh Lin y Jyh-Yih Chen. "Marine Antimicrobial Peptide TP4 Exerts Anticancer Effects on Human Synovial Sarcoma Cells via Calcium Overload, Reactive Oxygen Species Production and Mitochondrial Hyperpolarization". Marine Drugs 19, n.º 2 (5 de febrero de 2021): 93. http://dx.doi.org/10.3390/md19020093.
Texto completoSu, Bor-Chyuan, Chao-Chin Li, Jiun-Lin Horng y Jyh-Yih Chen. "Calcium-Dependent Calpain Activation-Mediated Mitochondrial Dysfunction and Oxidative Stress Are Required for Cytotoxicity of Epinecidin-1 in Human Synovial Sarcoma SW982 Cells". International Journal of Molecular Sciences 21, n.º 6 (19 de marzo de 2020): 2109. http://dx.doi.org/10.3390/ijms21062109.
Texto completoDelaloge, S., A. Yovine, A. Taamma, M. Riofrio, E. Brain, E. Raymond, P. Cottu et al. "Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity". Journal of Clinical Oncology 19, n.º 5 (1 de marzo de 2001): 1248–55. http://dx.doi.org/10.1200/jco.2001.19.5.1248.
Texto completoGarcia-Carbonero, R., J. G. Supko, J. Manola, M. V. Seiden, D. Harmon, D. P. Ryan, M. T. Quigley et al. "Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy". Journal of Clinical Oncology 22, n.º 8 (15 de abril de 2004): 1480–90. http://dx.doi.org/10.1200/jco.2004.02.098.
Texto completoAlthagbi, Hanan I., Walied M. Alarif, Khalid O. Al-Footy y Ahmed Abdel-Lateff. "Marine-Derived Macrocyclic Alkaloids (MDMAs): Chemical and Biological Diversity". Marine Drugs 18, n.º 7 (17 de julio de 2020): 368. http://dx.doi.org/10.3390/md18070368.
Texto completoMorgan, J. A., A. Le Cesne, S. Chawla, M. von Mehren, S. Schuetze, P. G. Casali, A. Nieto, Y. Elsayed, M. A. Izquierdo y G. D. Demetri. "Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I)". Journal of Clinical Oncology 25, n.º 18_suppl (20 de junio de 2007): 10060. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10060.
Texto completoJimeno, Jose, Robert G. Maki, Paolo Casali, Glynn Faircloth, Nerea Martinez, Antonio Nieto, Salvador Cañigueral y Kenneth Rinehart. "Therapeutic impact of ET-743 (Yondelis; trabectidin), a new marine-derived compound, in sarcoma". Current Opinion in Orthopaedics 14, n.º 6 (diciembre de 2003): 419–28. http://dx.doi.org/10.1097/00001433-200312000-00011.
Texto completoPierce, J. H. y S. A. Aaronson. "Myeloid cell transformation by ras-containing murine sarcoma viruses". Molecular and Cellular Biology 5, n.º 4 (abril de 1985): 667–74. http://dx.doi.org/10.1128/mcb.5.4.667-674.1985.
Texto completoPierce, J. H. y S. A. Aaronson. "Myeloid cell transformation by ras-containing murine sarcoma viruses." Molecular and Cellular Biology 5, n.º 4 (abril de 1985): 667–74. http://dx.doi.org/10.1128/mcb.5.4.667.
Texto completoPecoraro, Camilla, Francesca Terrana, Giovanna Panzeca, Barbara Parrino, Stella Cascioferro, Patrizia Diana, Elisa Giovannetti y Daniela Carbone. "Nortopsentins as Leads from Marine Organisms for Anticancer and Anti-Inflammatory Agent Development". Molecules 28, n.º 18 (5 de septiembre de 2023): 6450. http://dx.doi.org/10.3390/molecules28186450.
Texto completoShamai, Sivan y Ofer Merimsky. "Trabectedin for advanced soft tissue sarcoma: Ten-year real-life perspective." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): 11060. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.11060.
Texto completoHayashi, Keita, Peter Walde, Tatsuhiko Miyazaki, Kenshi Sakayama, Atsushi Nakamura, Kenji Kameda, Seizo Masuda, Hiroshi Umakoshi y Keiichi Kato. "Active Targeting to Osteosarcoma Cells and Apoptotic Cell Death Induction by the Novel Lectin Eucheuma serra Agglutinin Isolated from a Marine Red Alga". Journal of Drug Delivery 2012 (27 de diciembre de 2012): 1–11. http://dx.doi.org/10.1155/2012/842785.
Texto completoPonnusamy, Nirmaladevi, Rajasree Odumpatta, Pavithra Damodharan y Mohanapriya Arumugam. "Computational investigation of marine bioactive compounds reveals frigocyclinone as a potent inhibitor of Kaposi’s Sarcoma Associated Herpesvirus (KSHV) targets". Biomedical & Pharmacology Journal 12, n.º 3 (21 de agosto de 2019): 1289–302. http://dx.doi.org/10.13005/bpj/1757.
Texto completoGordon, Erlinda Maria, Victoria S. Chua, Ted T. Kim, Neal Shiv Chawla, Don Arlen Brigham, Ishrat Bhuiyan, Mark Agulnik, Warren Allen Chow y Sant P. Chawla. "A phase 2 study using ipilimumab, nivolumab, and trabectedin for previously untreated metastatic soft tissue sarcoma." Journal of Clinical Oncology 39, n.º 15_suppl (20 de mayo de 2021): 11562. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.11562.
Texto completoFares Amer, Nasrin y Tal Luzzatto Knaan. "Natural Products of Marine Origin for the Treatment of Colorectal and Pancreatic Cancers: Mechanisms and Potential". International Journal of Molecular Sciences 23, n.º 14 (21 de julio de 2022): 8048. http://dx.doi.org/10.3390/ijms23148048.
Texto completoSaada, Esma, Chahineze Rahal, Isabelle Ray Coquard, Antoine Italiano, Christine Chevreau, Nicolas Isambert, Binh Bui et al. "Rechallenge with trabectedin in patients with locally advanced or metastatic soft tissue sarcoma following drug holiday: The experience of the French Sarcoma Group (FSG)." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 10062. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10062.
Texto completoGrosso, F., G. D. Demetri, J. Y. Blay, I. Judson, A. Le Cesne, C. Spreafico, J. Jimeno, S. Pilotti, M. D’Incalci y P. G. Casali. "Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junio de 2006): 9511. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.9511.
Texto completoDileo, P., F. Grosso, M. Casanova, J. Jimeno, S. Marsoni, R. Sanfilippo, M. Podda, S. Ferrari, R. Bertulli y P. G. Casali. "Trabectedin (T) in metastatic Ewing's family tumors (EFT) patients (pts) progressing after standard chemotherapy". Journal of Clinical Oncology 25, n.º 18_suppl (20 de junio de 2007): 10040. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10040.
Texto completoSouid, Soumaya, Dorra Aissaoui, Najet Srairi-Abid y Khadija Essafi-Benkhadir. "Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response". Current Drug Targets 21, n.º 10 (28 de julio de 2020): 996–1007. http://dx.doi.org/10.2174/1389450121666200128161733.
Texto completoSanfilippo, Roberta, Giacomo Giulio Baldi, Elena Fumagalli, Andrea Marrari, Rossella Bertulli, Elena Palassini, Silvia Stacchiotti, Michela Libertini y Paolo Giovanni Casali. "Safety of trabectedin (T) in elderly patients (pts) with advanced soft tissue sarcoma (STS)." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 10576. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.10576.
Texto completoDembitsky, Valery, Tatyana Gloriozova y Vladimir Poroikov. "Antitumor Profile of Carbon-Bridged Steroids (CBS) and Triterpenoids". Marine Drugs 19, n.º 6 (3 de junio de 2021): 324. http://dx.doi.org/10.3390/md19060324.
Texto completoMartinez-Trufero, Javier, Isabel Pajares, Alba Hernandez Garcia, Ana Cebollero, Lourdes Calera y Antonio Anton. "Efficacy of trabectedin for advanced soft tissue sarcoma (ASTS): A retrospective single center analysis." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): e21509-e21509. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e21509.
Texto completoLe Cesne, Axel, Isabelle Ray-Coquard, Florence Duffaud, Christine Chevreau, Nicolas Penel, Binh Bui, Sophie Piperno-Neumann et al. "A large retrospective analysis of trabectedin in 885 patients with advanced soft tissue sarcoma." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): 10563. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.10563.
Texto completoKampmann, Eric, Dominique Harnicek, Ana Sofia Cardoso Martins, Berina Eppink, Eike Gallmeier, Lars Lindner, Roland Kanaar y Rolf D. Issels. "Heat-shock (H-S) and trabectedin efficacy in human soft-tissue sarcoma (STS) cells in vitro." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): e13540-e13540. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e13540.
Texto completoD'Incalci, Maurizio, Carlos Galmarini, Ines de la Riba Alvarez, Nadia Badri y Patrick Schöffski. "Association between body weight and efficacy outcomes during trabectedin therapy for recurrent advanced soft tissue sarcoma (STS)." Journal of Clinical Oncology 30, n.º 15_suppl (20 de mayo de 2012): 10047. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.10047.
Texto completoWang, Jun, Shihui Chen, Shiqiang Xu, Xing Yu, Dongqing Ma, Xiamin Hu y Xiaolu Cao. "In Vivo Induction of Apoptosis by Fucoxanthin, a Marine Carotenoid, Associated with Down-Regulating STAT3/EGFR Signaling in Sarcoma 180 (S180) Xenografts-Bearing Mice". Marine Drugs 10, n.º 12 (20 de septiembre de 2012): 2055–68. http://dx.doi.org/10.3390/md10092055.
Texto completoCioffi, A., A. LeCesne, J. Blay, S. Delaloge, A. Yovine, R. Maki, A. Nieto, J. J. Jiao y G. D. Demetri. "Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors". Journal of Clinical Oncology 27, n.º 15_suppl (20 de mayo de 2009): e13510-e13510. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e13510.
Texto completoChawla, Sant P., Victoria S. Chua-Alcala, Katherine Kim, Nupur Assudani, Ahmad Al-Shihabi, Ania Moradkhani, Doris Quon et al. "The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma." Journal of Clinical Oncology 37, n.º 8_suppl (10 de marzo de 2019): 22. http://dx.doi.org/10.1200/jco.2019.37.8_suppl.22.
Texto completoAljahdali, Mohammed Othman, Mohammad Habibur Rahman Molla y Foysal Ahammad. "Compounds Identified from Marine Mangrove Plant (Avicennia alba) as Potential Antiviral Drug Candidates against WDSV, an In-Silico Approach". Marine Drugs 19, n.º 5 (28 de abril de 2021): 253. http://dx.doi.org/10.3390/md19050253.
Texto completoPawłowska, Natalia, Anna Czajkowska, Anna Bielawska y Krzysztof Bielawski. "Ecteinascidins – new antineoplastic drugs from the depths of the seas". Postępy Higieny i Medycyny Doświadczalnej 72 (13 de diciembre de 2018): 1062–72. http://dx.doi.org/10.5604/01.3001.0012.7873.
Texto completoGordon, Erlinda M., Nadezhda Omelchenko, Samantha Jeffrey, Vaishali Kumar, Neal S. Chawla, Mahesh Seetharam, Victoria Chua et al. "Abstract CT287: LINNOVATE: A Phase 1/2 study of safety/efficacy using lurbinectedin, combined with ipilimumab, and nivolumab for advanced soft tissue sarcomas (NCT05876715)". Cancer Research 84, n.º 7_Supplement (5 de abril de 2024): CT287. http://dx.doi.org/10.1158/1538-7445.am2024-ct287.
Texto completoBlay, J., M. von Mehren, B. L. Samuels, M. P. Fanucchi, I. L. Ray-Coquard, B. Buckley, L. Gilles, C. Lebedinsky, Y. A. Elsayed y A. Le Cesne. "Combination of trabectedin (T) and doxorubicin (D) for the treatment of patients with soft tissue sarcoma (STS): Safety and efficacy analysis". Journal of Clinical Oncology 25, n.º 18_suppl (20 de junio de 2007): 10078. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10078.
Texto completoXiao, Jin-Fen, Marina Broz, Roberta Piras, Kristin Ishaya, Emily Ko y Jlenia Guarnerio. "Abstract 1364: Profiling tumor microenvironment for therapeutic intervention to soft-tissue sarcomas". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 1364. http://dx.doi.org/10.1158/1538-7445.am2023-1364.
Texto completoBehra, Biswadeep, S. Vairamuthu, Natesan Pazhanivel, Periyasamy Jalantha y Ganne Venkata Sudhakar Rao. "Histological and Immunohistochemical Features of Pulmonary Metastatic Oral Melanoma in a Labrador dog". Indian Journal of Veterinary Sciences & Biotechnology 18, n.º 5 (7 de noviembre de 2022): 119–22. http://dx.doi.org/10.48165/ijvsbt.18.5.24.
Texto completoGradl, Stefan, Sooncheol Lee, Martin Lange, Xiaoyun Wu, Silvia Goldoni, Timothy Lewis, Charlotte Kopitz et al. "Abstract ND04: BAY 2666605: The first PDE3A-SLFN12 complex inducer for cancer therapy". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): ND04. http://dx.doi.org/10.1158/1538-7445.am2022-nd04.
Texto completoLeone, Francesco, Caterina Peraldo-Neia, Giuliana Cavalloni, Marco Soster, Loretta Gammaitoni, Serena Marchiò y Massimo Aglietta. "Preclinical evidence of ET-743 as a potential chemotherapy option for the treatment of biliary carcinoma." Journal of Clinical Oncology 31, n.º 4_suppl (1 de febrero de 2013): 193. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.193.
Texto completoDel Campo, J., A. Roszak, T. Ciuleanu, M. Bidzinski, T. Hogberg, M. Wojtukienicz, K. Boman, A. Poveda, A. Westermann y M. Izquierdo. "Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary results". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junio de 2006): 5031. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5031.
Texto completoPeyraud, Florent, Jean-Philippe Guegan, Christophe Rey, Marina Pulido, Emmanuelle Bompas, Sophie Piperno-Neumann, Christine Chevreau et al. "Abstract 2578: High regulatory T cells infiltrate within tertiary lymphoid structure restricts response to immune checkpoint blockers in sarcomas". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 2578. http://dx.doi.org/10.1158/1538-7445.am2022-2578.
Texto completoSalazar, R., B. Pardo, M. Majem, M. García, A. Montes, C. Cuadra, E. Ciruelos, H. Cortés-Funes, C. Lebedinsky y L. Paz-Ares. "Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3h/q3w) in patients with advanced cancer and hepatic function disorder". Journal of Clinical Oncology 24, n.º 18_suppl (20 de junio de 2006): 2080. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.2080.
Texto completoSinko, J., J. Rajchard, Z. Balounova y L. Fikotova. " Biologically active substances from water invertebrates: a review". Veterinární Medicína 57, No. 4 (18 de mayo de 2012): 177–84. http://dx.doi.org/10.17221/5914-vetmed.
Texto completoBroz, Marina T., Marco DeSimone, Emily Ko, Roberta Piras y Jlenia Guarnerio. "Abstract A29: Uncovering transcriptional signatures of drug resistant tumor cells: Mechanisms of therapeutic resistance and opportunities for combination therapies". Cancer Immunology Research 10, n.º 12_Supplement (1 de diciembre de 2022): A29. http://dx.doi.org/10.1158/2326-6074.tumimm22-a29.
Texto completoBanella, Cristina, Laura Zocca, Alessia Boaretto, Gianluca Mattei, Marina Mola, Lara Ballerini, Lorito Nicla, Annalisa Tondo y Maura Calvani. "Abstract A108: Metabolic oriented treatment: efficacy of sr59230a 𝜷3-adrenergic receptor antagonist, and sr plus buformin® in Ewing sarcoma". Molecular Cancer Therapeutics 22, n.º 12_Supplement (1 de diciembre de 2023): A108. http://dx.doi.org/10.1158/1535-7163.targ-23-a108.
Texto completoBanella, Cristina, Francesco Carrozzo, Laura Zocca, Amada Pasha, Gianluca Mattei, Marina Mola, Lara Ballerini et al. "Abstract 1787: The β3-adrenergic receptor as novel target of metabolic phenotype in Ewing sarcoma". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 1787. http://dx.doi.org/10.1158/1538-7445.am2024-1787.
Texto completoZENETOS, A., S. KATSANEVAKIS, D. POURSANIDIS, F. CROCETTA, D. DAMALAS, G. APOSTOLOPOULOS, C. GRAVILI, E. VARDALA-THEODOROU y M. MALAQUIAS. "Marine alien species in Greek Seas: Additions and amendments by 2010". Mediterranean Marine Science 12, n.º 1 (11 de marzo de 2011): 95. http://dx.doi.org/10.12681/mms.55.
Texto completoBroz, Marina, Emily Ko, Jinfen Xiao, Marco DeSimone, Roberta Piras, Kristin Ishaya, Xen Ping Hoi y Jlenia Guarnerio. "Abstract 1255: Glucose dependent CD73+ CAFs enforce a tumor metabolic barrier that promotes T cell exclusion". Cancer Research 83, n.º 7_Supplement (4 de abril de 2023): 1255. http://dx.doi.org/10.1158/1538-7445.am2023-1255.
Texto completoLee, Meng-Chou, Chin-Yi Huang, Chin-Ling Lai, Han-Yang Yeh, Jing Huang, Wei Qing Chloe Lung, Po-Tsang Lee y Fan-Hua Nan. "Colaconema formosanum, Sarcodia suae, and Nostoc commune as Fermentation Substrates for Bioactive Substance Production". Fermentation 8, n.º 7 (21 de julio de 2022): 343. http://dx.doi.org/10.3390/fermentation8070343.
Texto completoGolozubova, Julia Sergeevna, Lyubov Stepanovna Buzoleva, Elena Aleksandrovna Bogatyrenko, Alexandra Vyacheslavovna Kim y Alena Igorevna Eskova. "Diversity of cultivated heterotrophic bacteria selected from surface waters of the Vostok Bay of the Japanese Sea". Samara Journal of Science 6, n.º 4 (1 de diciembre de 2017): 32–35. http://dx.doi.org/10.17816/snv201764106.
Texto completoAtmaca, Harika, Emir Bozkurt, Burcu Cakar, Zeki Gokhan Surmeli, Selim Uzunoglu, Ruchan Uslu y Burcak Karaca. "Trabectedin to induce mitochondrial membrane potential dissipation and reactive oxygen species generation in breast cancer cells." Journal of Clinical Oncology 31, n.º 15_suppl (20 de mayo de 2013): e13580-e13580. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e13580.
Texto completoTaamma, A., J. L. Misset, M. Riofrio, C. Guzman, E. Brain, L. Lopez Lazaro, H. Rosing, J. M. Jimeno y E. Cvitkovic. "Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors". Journal of Clinical Oncology 19, n.º 5 (1 de marzo de 2001): 1256–65. http://dx.doi.org/10.1200/jco.2001.19.5.1256.
Texto completoGanapathi, Shireen S., Emma Wrenn, Nicolas Garcia, Neerja Katiyar, Aya Miyaki, Yuqi Kang, Marina Chan, Taran S. Gujral y Elizabeth R. Lawlor. "Abstract 150: Transcriptional rewiring of BET inhibitor treated Ewing sarcoma cells augments their dependency on focal adhesion kinase". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 150. http://dx.doi.org/10.1158/1538-7445.am2024-150.
Texto completo